iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating)’s share price traded down 6.3% during mid-day trading on Tuesday . The stock traded as low as $16.51 and last traded at $16.91. 145,109 shares traded hands during mid-day trading, a decline of 45% from the average session volume of 264,273 shares. The stock had previously closed at […]
iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) – Equities researchers at HC Wainwright upped their Q2 2023 EPS estimates for shares of iTeos Therapeutics in a note issued to investors on Thursday, May 11th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($1.13) for the quarter, up […]
iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) – Wedbush reduced their Q2 2023 EPS estimates for shares of iTeos Therapeutics in a note issued to investors on Wednesday, May 10th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.73) per share for the quarter, down from their prior estimate of ($0.58). Wedbush […]
iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) saw a large growth in short interest in March. As of March 31st, there was short interest totalling 1,690,000 shares, a growth of 11.2% from the March 15th total of 1,520,000 shares. Approximately 5.8% of the company’s stock are sold short. Based on an average trading volume of […]
Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) were down 2.9% on Tuesday . The stock traded as low as $14.11 and last traded at $14.11. Approximately 4,403 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 273,655 shares. The stock had previously closed at $14.53. Wall […]